Colorado Prescription Drug Affordability Review Board & Advisory Council
Colorado’s Prescription Drug Affordability Board (PDAB), established under Senate Bill 21-175 and updated under House Bill 23-1225, is a Type-1 Board within the Division of Insurance that has the authority to review prescription drug costs and evaluate their impact on Coloradans through affordability reviews of prescription drugs. The Board may then recommend ways to address those costs and may set an upper payment limit for certain prescription drugs.
PDAB Meetings & Materials
The next PDAB Meeting will be held Friday, June 7 from 10 am-2 pm MT.
PDAAC Meetings & Materials
The PDAAC will meet next at a joint PDAB/PDAAC meeting on Friday, July 19 at 10 am MT.
Register for July 19 PDAB/PDAAC Meeting
The PDAAC is currently recruiting new council members to represent the following stakeholders: Labor unions, health care professionals with prescribing authority, and manufacturers of generic drugs.
If you are interested in serving a 3-year term on the PDAAC, please fill out the application below.
Meeting Links & Recordings
Links to upcoming meetings and PDAB and PDAAC meeting recordings can be found below.
Contact Us
PDAB Listserv: To receive PDAB and PDAAC updates directly in your inbox, click here. To subscribe, you will need to enter your email and then choose Updates From Divisions > Division of Insurance > Division of Insurance Prescription Drug Affordability Board.
How to Provide Public Comment at PDAB Meetings
- Verbal Public Comment: To provide verbal comments, please fill out the sign up sheet that will be provided at the beginning of each meeting. Public comments will be limited to 2 minutes per person.
- Written Public Comment: To provide written comments about general PDAB business or agenda items, please email dora_ins_pdab@state.co.us. Written comments will be accepted up to 48 hours before each meeting. Comments submitted after the 48-hour deadline will be considered for the following meeting.
Affordability Reviews
Affordability Review Process
Prescription Drugs Selected for Affordability Review
- PDAB Members
The Prescription Drug Affordability Board (PDAB) is a 5 member Type-1 Board tasked with the following statutory duties:
Identify drugs that may be subject to an affordability review; Conduct affordability reviews on selected eligible drugs; Determine whether a prescription drug is unaffordable for Colorado consumers; If a drug is found to be unaffordable, the Board may set an upper payment limit; Make policy recommendations to the General Assembly.
The Governor has appointed the following members to the PDAB:
- Sami Diab, MD of Greenwood Village, Colorado
- Amarylis “Amy” Gutierrez, PharmD of Aurora, Colorado
- Catherine Harshbarger of Holyoke, Colorado
- Gail Mizner, MD, FACP, AAHIVS of Snowmass Village, Colorado and to serve as Board Chair
- James Justin VandenBerg, PharmD, BCPS of Denver, Colorado
- PDAAC Members
The Board appointed the 15 member Prescription Drug Affordability Advisory Council (PDAAC) to provide stakeholder input on prescription drug affordability. All PDAAC members meet statutory requirements for composition, geographic representation, and subject matter expertise.
To the extent possible, the Board appointed members who have experience serving underserved communities and who reflect the state’s diversity in terms of race, immigration status, income, disability, age, gender identity, and geography.
Council Members:
- Kim Bimestefer Executive Director of HCPF
- Gail deVore representing health care consumers
- Sarita Parikh representing health care consumers
- Edward A. Dauer, LL.B., M.P.H. representing statewide health care advocacy organizations
- Kimberley Jackson, DO representing consumers with chronic diseases and PDAAC Chair
- Applications open for individuals representing a labor union
- Nathan Wilkes representing employers
- Chad Friday representing carriers
- Marc Reece representing pharmacy benefit managers
- Applications open for individuals representing health care professionals with prescribing authority
- R. Brett McQueen, PhD representing an organization that researches prescription drugs
- Katelin Lucariello MPH representing manufacturers of brand name drugs
- Neal Miller representing manufacturers of generic drugs
- Andrew Gonzales, PharmD representing pharmacists
- Leah Lindahl representing wholesalers
- Conflicts of Interest
Information required to be disclosed pursuant to §10-16-1402(3)(d) will be contained here.
- Colorado PDAB 2023 Eligible Drug Dashboard
- Learning Series & Resources
Slides and recordings for the five part Prescription Drug Affordability Learning Series can be found below.
Learning Series 1: Data Deep Dive
Learning Series 2: Patient Perspectives
Learning Series 3: Pharmaceutical Supply Chain Panel
View Pharmaceutical Supply Chain Panel
Learning Series 4: Comparative Effectiveness & Affordability
View Comparative Effectiveness & Affordability
Learning Series 5: Prescription Drug Affordability Efforts in Colorado & Other States
View Prescription Drug Affordability Efforts in Colorado & Other States
Resources
Reducing Prescription Drug Costs in Colorado, 2nd Edition
CIVHC Top 100 Brand and Generic Commercial Payer Prescription Drugs